---
title: "Fecal Microbiome and Metabolome During Immunotherapy-Based Total Neoadjuvant Therapy in Rectal Can"
id: "frontiers-in-immunology-11-commentary-fecal-microbiome-and-metabolome-dynamics-during-immunotherapy-based"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-commentary-fecal-microbiome-and-metabolome-dynamics-during-immunotherapy-based"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1981594"
published_at: "2026-11-05T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Fecal Microbiome and Metabolome During Immunotherapy-Based Total Neoadjuvant Therapy in Rectal Can
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-commentary-fecal-microbiome-and-metabolome-dynamics-during-immunotherapy-based
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1981594)
- **Published At:** 2026-11-05T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source is a published commentary addressing interactions between the **fecal microbiome** and **metabolome** during **immunotherapy**-based **total neoadjuvant therapy** (TNT) in **rectal cancer**; the piece framed associations with both treatment response and toxicity. - The available text did not include original trial data, numerical results, or sample-size information; the commentary format means authors interpreted existing literature rather than reporting a primary cohort. - The commentary reportedly discussed dynamic changes in stool microbial composition and metabolite profiles over the course of TNT combined with immunotherapy, but the source did not provide specific taxa, metabolite names, or temporal sampling schedules. - Authors linked microbiome/metabolome patterns conceptually to differential **treatment response** and to immune-related or gastrointestinal **toxicity**, yet no statistical associations, effect sizes, or significance levels were presented in the accessible source content. - The commentary outlined mechanistic hypotheses connecting microbial metabolites to antitumor immunity and mucosal inflammation; mechanistic experiments, however, were not described in the source. - Clinical utility and translational implications—such as biomarkers for patient selection, risk stratification for toxicity, or microbiome-directed interventions—were discussed at a conceptual level; specific interventional protocols were not reported. - The source did not include trial endpoints, dosing regimens, timing of immunotherapy relative to TNT, or details on methods for microbiome/metabolome profiling (e.g., sequencing platforms, metabolomics techniques). - The commentary flagged gaps and unanswered questions in the literature and recommended further prospective studies; exact next-step study designs or regulatory milestones were not provided in the available content.
## Clinical Analysis & Structured Key Points
Frontiers | Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity GENERAL COMMENTARY article Front. Immunol. , 05 November 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1981594 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic Microbiota-Immune Interactions: A New Frontier in Cancer Treatment Optimization Volume II Submission open 8886 views 5 articles Editor & Reviewers Edited by L M Lorenzo Mortara Reviewed by N P Nitesh Priyadarshi X L Xiaojun Liu Outline Figures and Tables Table 1 Observations on Lu et al. ( 1 ), their interpretive consequences, and suggested next steps. View in article GENERAL COMMENTARY article Front. Immunol. , 05 November 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1981594 Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity B L Bingqiang Li 1 C S Chenyu Song 1 H L Hang Li 1 Z L Zhongkun Li 1 Z W Zhe Wang 1 K Y Kunpeng Yang 1,2 W S Wenjuan Sun 2 B W Bao Wang 1,2 * 1. Jilin Cancer Hospital, Changchun, Jilin, China 2. Changchun University of Chinese Medicine, Changchun, Jilin, China Article metrics View details This article is a commentary on: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity Read original article A Commentary on Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity By Lu W, Wang Y, Zhang J, Li Y, Huang L, Yang W, Zhou S, Zhou M, Chen Y, Wu R, Wang Y, Zhang H, Wan J, Xia F, Zhang Z and Shen L (2026). Front. Immunol. 17:1871586. doi: 10.3389/fimmu.2026.1871586 Introduction We read with great interest the article by Lu et al. ( 1 ), reporting a longitudinal fecal microbiome–metabolome study nested within the randomized phase II TORCH trial (NCT04518280) of immunotherapy-based total neoadjuvant therapy (iTNT) for microsatellite-stable locally advanced rectal cancer (pMMR/MSS) ( 2 ). The authors profiled 102 stool samples across three treatment timepoints. They show that short-course radiotherapy-based iTNT reorganizes rather than depletes the gut ecosystem, and they nominate baseline taxa and metabolites associated with response and toxicity. They then move beyond correlation: oral gamma-aminobutyric acid (GABA) blunts the antitumor effect of radiotherapy plus PD-1 blockade in vivo . Longitudinal multi-omics within a randomized trial, coupled with functional testing, is demanding, and the authors’ framing of causality is exemplary. We offer four observations to extend its translational reach ( Table 1 ). Table 1 Domain As reported by Lu et al. Our interpretation Suggested next step Response definition Methods classify pathological complete response (pCR), clinical complete response (cCR) and near-complete response as responders; Results define responders as pCR or cCR The 29 versus 15 split may not survive the stricter definition, and the feature list may change with it State which definition produced each analysis; report the split and the discriminating features under both, and separately after excluding near-responders Outcome anchoring Endpoint is response at restaging; regrowth-free and TME-free survival are not analyzed Restaging response is an imperfect proxy for organ preservation: cCR sensitivity for ypT0 37.5% and positive predictive value 68.2% ( 3 ); in suspected regrowth, endoscopy predicts pCR better than MRI (OR 8.2 versus 2.11) ( 4 ); 2-year regrowth after cCR 25.2% ( 5 ); 3-year TME-free survival 41–53% ( 6 ) Re-test candidate features against regrowth-free and TME-free survival as follow-up matures Cohort representativeness 44 baseline samples from 121 evaluable TORCH participants ( 2 ) Responders 29/44 (66%, 95% CI 51–78%) versus 56.5% and 54.2% by arm; compatible with enrichment, but too imprecise to establish it Compare sampled with unsampled participants on baseline, treatment and outcome variables Longitudinal attrition 44 to 37 to 21 samples; recent antibiotic exposure precluded sampling Patients with infection or febrile neutropenia may be selectively missing, which would attenuate rather than inflate the reported toxicity associations Report the reason for each missing sample; repeat toxicity analyses with inverse-probability weighting or a complete-case sensitivity analysis Unmeasured confounding Diet and comedication not modeled; mean age 54 years Proton-pump inhibitors and metformin are among the strongest non-antibiotic modifiers of gut composition ( 7 , 8 ) Collect dietary and comedication data prospectively; pre-specify older and polypharmacy subgroups in the validation cohort Statistical validation Random-forest selection and ROC analysis in the same 44 patients; combined model AUC 72.6% versus 73.8% for K. pneumoniae alone; metabolite scores correlated with the indices used to fit them In-sample optimism; model fit is reported in place of predictive validity Nested cross-validation with feature selection inside the inner folds; independent hold-out in UNION or STELLAR II; decision curve analysis ( 10 ); state where Benjamini–Hochberg correction was applied Table presentation Lu et al.’s Table 1 is titled “Baseline characteristics” and includes diarrhea grade, blood-toxicity score and blood-cell counts In our reading these are on-treatment values, and may be misread as pretreatment characteristics Separate baseline from on-treatment variables, or retitle the table Causal attribution Oral GABA at 6 mg/mL; K. pneumoniae linked to GABA through correlation with K00128; subcutaneous MC38 model Exogenous GABA can impair radiotherapy–PD-1 synergy; this does not show that microbial GABA reaches comparable concentrations, and GABAergic effects are context-dependent ( 12 , 13 ) Gnotobiotic colonization with wild-type versus GABA-pathway-deficient K. pneumoniae, stable-isotope tracing, receptor antagonism, and targeted GABA quantification in serum and tumor Observations on Lu et al. ( 1 ), their interpretive consequences, and suggested next steps. TME, total mesorectal excision; cCR, clinical complete response; pCR, pathological complete response; ROC, receiver operating characteristic; AUC, area under the curve; MRI, magnetic resonance imaging; OR, odds ratio; CI, confidence interval; GABA, gamma-aminobutyric acid; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair; MSI-H, microsatellite instability–high; MSS, microsatellite stable. Anchoring biomarkers to organ preservation Response classification merits clarification: the Methods count near-complete response as a responder, whereas the Results define responders as achieving a pathological or clinical complete response. Because near-complete response is the least reproducibly assessed category, whether the reported 29 versus 15 split survives the stricter definition, and whether the discriminating features retain significance once near-responders are excluded, should be reported. More fundamentally, restaging response is a surrogate: clinical complete response detects ypT0 with low sensitivity (37.5%) and a positive predictive value of only 68.2% ( 3 ), and endoscopy predicts pCR better than magnetic resonance imaging when regrowth is suspected ( 4 ). Durability is also imperfect: 2-year local regrowth after cCR was 25.2% ( 5 ), and 3-year total mesorectal excision (TME)-free survival in OPRA was 41–53% ( 6 ). Features tracking initial response may therefore not track organ preservation. Re-testing them against regrowth-free and TME-free survival as TORCH matures would speak directly to the watch-and-wait decision. Who was sampled The 44 baseline samples are roughly one third of the 121 evaluable TORCH participants ( 2 ), and the responder proportion here (29/44, 66%; 95% confidence interval 51–78%) is numerically higher than the trial’s 56.5% and 54.2% by arm; the interval spans both, so enrichment is plausible rather than established. Comparing sampled with unsampled participants on baseline, treatment and outcome variables is therefore a prerequisite. Attrition compounds this: 44, then 37, then 21 samples. Because recent antibiotic exposure precluded sampling, patients with febrile neutropenia or infection—those at the severe end of the toxicity spectrum the study seeks to predict—are liable to be selectively absent later, which would attenuate rather than inflate the reported toxicity associations. The authors should report why each sample is missing and repeat the toxicity analyses with inverse-probability weighting or a complete-case analysis. Residual confounding from diet and supportive care is candidly flagged; proton-pump inhibitors and metformin are among the strongest non-antibiotic determinants of gut community structure ( 7 , 8 ), so prospective capture is preferable to post hoc adjustment. Statistical optimism Lu et al. label these analyses exploratory, so our point is narrower: several inferential steps occur within the same 44-patient dataset. Random-forest selection followed by receiver operating characteristic (ROC) analysis there yields optimistic discrimination, and the combined Klebsiella pneumoniae–GABA model (area under the curve 72.6%) performed no better than K. pneumoniae alone (73.8%): instability rather than evidence that GABA adds nothing. The metabolite-derived toxicity scores compound this: built from coefficients fitted to the hematologic indices and correlated with those same indices, they quantify fit, not predictive validity. Three remedies would make the next iteration decisive: nested cross-validation with feature selection inside inner folds; independent hold-out testing in an external short-course iTNT cohort such as UNION or STELLAR II, an approach already feasible for fecal metagenomic signatures ( 9 ); and decision curve analysis. The last matters because net benefit rather than discrimination determines whether a toxicity model changes prophylaxis, dosing or surveillance ( 10 ). Out-of-sample testing is nearer than it may appear: a prospective fecal metagenomic series has already been reported from UNION, profiling 77 samples from 36 patients across three treatment timepoints, 19 of them in the short-course arm ( 11 ). It is small, and its authors call the findings exploratory and in need of validation in larger cohorts, so it would serve better to falsify a candidate signature than to confirm one; but it is independently recruited and uses a different PD-1 antibody, which makes it a demanding test. It would also help to state where Benjamini–Hochberg correction was applied, and which of the 94 toxicity-associated metabolites screened at |r| > 0.3 with P < 0.05 survive it. From association to causation The in vivo experiment is the paper’s most distinctive contribution, but its interpretation could be sharpened. The link from K. pneumoniae to luminal GABA rests on correlation with a single KEGG ortholog (K00128, an aldehyde dehydrogenase), while the mouse experiment supplies GABA systemically at 6 mg/mL; this shows that exogenous GABA can impair radiotherapy–PD-1 synergy, not that microbial GABA does so at patient-relevant concentrations. The direction is not fixed either: enhancing type A GABA receptor signaling with a benzodiazepine potentiated radiotherapy and anti–PD-L1 activity in melanoma models ( 12 ), whereas cancer-cell-derived GABA is immunosuppressive ( 13 ), so the net effect may depend on tumor type, receptor subtype, and whether the pool is local or systemic. Subcutaneous MC38 tumors with focal irradiation also reproduce neither pelvic irradiation nor rectal mucosa. Gnotobiotic colonization contrasting wild-type with GABA-pathway-deficient K. pneumoniae, stable-isotope tracing, and a receptor-antagonism rescue arm with targeted GABA quantification in serum and tumor would separate microbial from tumor-intrinsic sources. Future directions These points argue for a shift from discovery toward validation. Prospective harmonization of sampling window, extraction protocol and outcome dictionary across ongoing short-course iTNT programs such as UNION and STELLAR II would help ( 14 , 15 ), given that pooled analysis with earlier cohorts was precluded by heterogeneity ( 1 , 16 – 18 ). A validated signal should be reduced to a low-cost targeted assay, such as quantitative PCR for Klebsiella with quantification of GABA, aspartate and taurine, subject to analytical validation and pre-specified decision thresholds. Two boundaries deserve statement: our critique is confined to pMMR/MSS disease, since dMMR/MSI-H tumors respond to PD-1 blockade alone and should not be equated with it ( 19 ); and because response-associated commensals overlap with taxa linked to immune-related adverse events ( 20 , 21 ), any interventional step warrants randomized evaluation first. Concluding remarks None of this diminishes the achievement. Lu et al. have produced an integrated longitudinal fecal microbiome–metabolome resource for iTNT in microsatellite-stable rectal cancer and have taken the uncommon step of functionally interrogating their leading metabolite instead of stopping at association. We have made four suggestions: response definitions anchored to organ preservation, transparent accounting of who was sampled, out-of-sample validation, and mechanistic dissection of the GABA axis. We raise them because this dataset is worth the additional work. Statements Author contributions BL: Writing – original draft. CS: Writing – original draft. HL: Writing – original draft. ZL: Writing – original draft. ZW: Writing – original draft. KY: Writing – original draft. WS: Writing – original draft. BW: Writing – review & editing. Funding The author(s) declared that financial support was not received for this work and/or its publication. Conflict of interest The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Generative AI statement The author(s) declared that generative AI was used in the creation of this manuscript. A generative artificial intelligence tool was used solely for English language editing of author-written text. It was not used for study design, data extraction, data analysis, interpretation of results, or preparation of the figure. The authors reviewed and edited all output and take full responsibility for the content of the manuscript. Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. References 1 Lu W Wang Y Zhang J Li Y Huang L Yang W et al . Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity . Front Immunol . ( 2026 ) 17 : 1871586 . doi: 10.3389/fimmu.2026.1871586 Pubmed Abstract CrossRef Google Scholar 2 Xia F Wang Y Wang H Shen L Xiang Z Zhao Y et al . Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH) . J Clin Oncol . ( 2024 ) 42 : 3308–18 . doi: 10.1200/JCO.23.02261 Pubmed Abstract CrossRef Google Scholar 3 Deidda S Spolverato G Capelli G Bao RQ Bettoni L Crimi F et al . Limits of clinical restaging in detecting responders after neoadjuvant therapies for rectal cancer . Dis Colon Rectum . ( 2023 ) 66 : 957–64 . doi: 10.1097/DCR.0000000000002450 Pubmed Abstract CrossRef Google Scholar 4 Yeung TM Rosen RY Bercz A Williams H Omer D Verheij FS et al . The value of MRI and flexible sigmoidoscopy in detecting tumor regrowth in watch and wait rectal cancer patients undergoing active surveillance after total neoadjuvant therapy . Surg Endosc . ( 2025 ) 39 : 5669–75 . doi: 10.1007/s00464-025-11982-0 Pubmed Abstract CrossRef Google Scholar 5 van der Valk MJM Hilling DE Bastiaannet E Meershoek-Klein Kranenbarg E Beets GL Figueiredo NL et al . Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study . Lancet . ( 2018 ) 391 : 2537–45 . doi: 10.1016/S0140-6736(18)31078-X Pubmed Abstract CrossRef Google Scholar 6 Garcia-Aguilar J Patil S Gollub MJ Kim JK Yuval JB Thompson HM et al . Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy . J Clin Oncol . ( 2022 ) 40 : 2546–56 . doi: 10.1200/JCO.22.00032 Pubmed Abstract CrossRef Google Scholar 7 Vich Vila A Collij V Sanna S Sinha T Imhann F Bourgonje AR et al . Impact of commonly used drugs on the composition and metabolic function of the gut microbiota . Nat Commun . ( 2020 ) 11 : 362 . doi: 10.1038/s41467-019-14177-z Pubmed Abstract CrossRef Google Scholar 8 Maier L Pruteanu M Kuhn M Zeller G Telzerow A Anderson EE et al . Extensive impact of non-antibiotic drugs on human gut bacteria . Nature . ( 2018 ) 555 : 623–8 . doi: 10.1038/nature25979 Pubmed Abstract CrossRef Google Scholar 9 Wirbel J Pyl PT Kartal E Zych K Kashani A Milanese A et al . Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer . Nat Med . ( 2019 ) 25 : 679–89 . doi: 10.1038/s41591-019-0406-6 Pubmed Abstract CrossRef Google Scholar 10 Vickers AJ Elkin EB . Decision curve analysis: a novel method for evaluating prediction models . Med Decis Making . ( 2006 ) 26 : 565–74 . doi: 10.1177/0272989X06295361 Pubmed Abstract CrossRef Google Scholar 11 You Q Jin M Zhou B Huang C Lin Z Hu J et al . Gut microbiome components predict response to neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): a prospective study . Front Pharmacol . ( 2026 ) 17 : 1829108 . doi: 10.3389/fphar.2026.1829108 Pubmed Abstract CrossRef Google Scholar 12 Pomeranz Krummel DA Nasti TH Kaluzova M Kallay L Bhattacharya D Melms JC et al . Melanoma cell intrinsic GABA(A) receptor enhancement potentiates radiation and immune checkpoint inhibitor response by promoting direct and T cell-mediated antitumor activity . Int J Radiat Oncol Biol Phys . ( 2021 ) 109 : 1040–53 . doi: 10.1016/j.ijrobp.2020.10.025 Pubmed Abstract CrossRef Google Scholar 13 Huang D Wang Y Thompson JW Yin T Alexander PB Qin D et al . Cancer-cell-derived GABA promotes beta-catenin-mediated tumour growth and immunosuppression . Nat Cell Biol . ( 2022 ) 24 : 230–41 . doi: 10.1038/s41556-021-00820-9 Pubmed Abstract CrossRef Google Scholar 14 Lin ZY Zhang P Chi P Xiao Y Xu XM Zhang AM et al . Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial . Ann Oncol . ( 2024 ) 35 : 882–91 . doi: 10.1016/j.annonc.2024.06.015 Pubmed Abstract CrossRef Google Scholar 15 Tang Y Li HY Wei LC Li N Zhang WJ Lu YF et al . Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer
## Related Clinical Research

- [Metformin use and incident breast cancer risk: time-bias–aware meta-analysis and limits for imegli](https://medichelpline.com/clinical-feed/medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and.md)
- [Metabolic reprogramming in the immune microenvironment of Ewing sarcoma — article page summary](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-metabolic-reprogramming-in-the-immune-microenvironment-of-ewing-sarcoma-from.md)
- [YTHDF2 promotes cutaneous melanoma progression via m6A-dependent HMOX1 regulation of ferroptosis](https://medichelpline.com/clinical-feed/pubmed-42848283.md) (DOI: 10.1007/s12032-026-03427-y)
- [Targeting VISTA for Skin Cancer Immunotherapy: Source Article Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-vista-as-a-novel-immunotherapy-for-skin-cancer.md)
- [Metformin, antibiotics, painkillers, and PPIs alter the gut microbiome and affect colorectal neopl](https://medichelpline.com/clinical-feed/medrxiv-10-metformin-antibiotics-painkillers-and-proton-pump-inhibitors-shape-the-gut.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.